China SXT Pharmaceuticals, Inc. (SXTC) stock forecast & analysis
2.83
NasdaqCM · USD
Up: +1.58, +126.4%
1 analysis
Latest analysis: · verdict locked
- Open
- 3.21
- Previous close
- 1.25
- Day range
- 1.87 – 9.59
- 52-week range
- 1.18 – 83,760.00
- Volume (shares)
- 144.84M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 1.32M
- P/E ratio
- Not available
- Dividend yield
- 0.00%
- Beta
- 1.86
- Market cap
- 3.74M
Market Scanner’s AI analysis of China SXT Pharmaceuticals, Inc. (SXTC), updated October 2026: Share consolidation and direct offering news preceded SXTC's recent price declines and revenue drop.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of China SXT Pharmaceuticals, Inc. (SXTC) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
Share consolidation and direct offering news preceded SXTC's recent price declines and revenue drop.
Recent analyses for SXTC covered a significant year-over-year revenue decline of -43.9% and negative earnings, with TTM revenue at $1,138,052. Market indicators showed the stock price below its 50-day and 200-day SMAs, suggesting a medium-term and long-term downtrend, though the 10-day EMA indicated some short-term upward momentum. News highlighted a share consolidation announced in August 2026 and a $9 million registered direct offering closed in July 2026, with the stock frequently appearing among premarket decliners.
SXTC news & sentiment
News headlines indicated mixed to negative sentiment for SXTC, frequently categorizing it among top premarket decliners. Coverage noted a share consolidation and a registered direct offering, alongside ongoing downward price pressure.
SXTC technical picture
The stock price was below its 50-day and 200-day Simple Moving Averages, indicating a medium-term and long-term downtrend. Momentum readings, including the RSI and MACD, suggested weakening and bearish momentum, respectively, though the 10-day Exponential Moving Average showed some short-term upward movement. The Money Flow Index indicated strong buying pressure, and the price was trading within the Bollinger Bands.
Fundamentals
The company's revenue has shown a significant year-over-year decline, with annual revenues trending downwards. Profitability is negative, reflected in both EPS and Return on Equity TTM. The company has a market capitalization of $3,739,612 and a dividend yield of 0%.
Factors discussed — upside
- Money Flow Index (MFI) at 97.45 suggests strong buying pressure.
- 10-day Exponential Moving Average (EMA) below current price indicates short-term upward momentum.
Factors discussed — risks
- Current price 14.7% below 50-day SMA indicates medium-term downtrend.
- Current price 99.8% below 200-day SMA reinforces long-term bearish outlook.
- Relative Strength Index (RSI) at 34.90 indicates weakening momentum.
- MACD below signal line indicates bearish momentum.
- Quarterly Revenue Growth YOY at -43.9%.
- Market technicals
- Financial performance
- Corporate actions
- Stock price trends
Summary updated .
SXTC technical indicators
Common technical indicators for SXTC, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 3.32 | Price below |
| 10-day exponential moving average | 2.40 | Price above |
| Relative strength index (14-day) | 34.91 | Neutral |
| MACD line (12/26/9) | -3.0885 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 1.69 – 3.20 | Price inside the bands |
Analyses
Recent SXTC.US analyses are locked — sign in to read them or generate a fresh one.
Locked
Unlock in the library — 1 newer report
Sign in to unlock the 2026-10-08 SXTC.US analysis
Get the verdict — free
Frequently asked questions
- What is the bull case for China SXT Pharmaceuticals, Inc.?
- The Money Flow Index (MFI) at 97.45 suggests strong buying pressure, and the 10-day Exponential Moving Average (EMA) below the current price indicates some short-term upward momentum.
- What are the risks for China SXT Pharmaceuticals, Inc.?
- The company's price is below its 50-day and 200-day Simple Moving Averages (SMAs), indicating a medium-term and long-term downtrend, respectively. The Relative Strength Index (RSI) at 34.90 shows weakening momentum, and the MACD is below its signal line, suggesting bearish momentum. Furthermore, quarterly revenue has declined year-over-year by 43.9%.
- Is China SXT Pharmaceuticals, Inc. bullish or bearish?
- Recent AI analyses of China SXT Pharmaceuticals, Inc. examined factors on both sides. Discussed upside: The Money Flow Index (MFI) at 97.45 suggests strong buying pressure, and the 10-day Exponential Moving Average (EMA) below the current price indicates some short-term upward momentum. Discussed risks: The company's price is below its 50-day and 200-day Simple Moving Averages (SMAs), indicating a medium-term and long-term downtrend, respectively. The Relative Strength Index (RSI) at 34.90 shows weakening momentum, and the MACD is below its signal line, suggesting bearish momentum. Furthermore, quarterly revenue has declined year-over-year by 43.9%. These are descriptive observations, not a recommendation.
- What is the latest sentiment on China SXT Pharmaceuticals, Inc.?
- News headlines indicated mixed to negative sentiment for SXTC, frequently categorizing it among top premarket decliners. Coverage noted a share consolidation and a registered direct offering, alongside ongoing downward price pressure.
- How does Market Scanner analyse China SXT Pharmaceuticals, Inc.?
- Every analysis of China SXT Pharmaceuticals, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for China SXT Pharmaceuticals, Inc.?
The Money Flow Index (MFI) at 97.45 suggests strong buying pressure, and the 10-day Exponential Moving Average (EMA) below the current price indicates some short-term upward momentum.
What are the risks for China SXT Pharmaceuticals, Inc.?
The company's price is below its 50-day and 200-day Simple Moving Averages (SMAs), indicating a medium-term and long-term downtrend, respectively. The Relative Strength Index (RSI) at 34.90 shows weakening momentum, and the MACD is below its signal line, suggesting bearish momentum. Furthermore, quarterly revenue has declined year-over-year by 43.9%.
Is China SXT Pharmaceuticals, Inc. bullish or bearish?
Recent AI analyses of China SXT Pharmaceuticals, Inc. examined factors on both sides. Discussed upside: The Money Flow Index (MFI) at 97.45 suggests strong buying pressure, and the 10-day Exponential Moving Average (EMA) below the current price indicates some short-term upward momentum. Discussed risks: The company's price is below its 50-day and 200-day Simple Moving Averages (SMAs), indicating a medium-term and long-term downtrend, respectively. The Relative Strength Index (RSI) at 34.90 shows weakening momentum, and the MACD is below its signal line, suggesting bearish momentum. Furthermore, quarterly revenue has declined year-over-year by 43.9%. These are descriptive observations, not a recommendation.
What is the latest sentiment on China SXT Pharmaceuticals, Inc.?
News headlines indicated mixed to negative sentiment for SXTC, frequently categorizing it among top premarket decliners. Coverage noted a share consolidation and a registered direct offering, alongside ongoing downward price pressure.
How does Market Scanner analyse China SXT Pharmaceuticals, Inc.?
Every analysis of China SXT Pharmaceuticals, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.
Read the methodology- Bundles used
- gemini-low-v2
Run a fresh SXTC.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.